• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, November 9, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home Headlines

UTA, UT Southwestern findings challenge current approach to Glut1…

Bioengineer.org by Bioengineer.org
January 25, 2018
in Headlines, Health, Science News
Reading Time: 3 mins read
1
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: UTA

Researchers at The University of Texas at Arlington and the University of Texas Southwestern Medical Center have discovered that diet changes and early diagnosis could help outcomes for patients with Glucose Transporter Type 1 Deficiency, a rare pediatric neurological disorder that can cause motor developmental problems and trigger seizures and epilepsy.

"We set out to clarify issues surrounding the diagnosis and treatment of the disease through the creation of the first registry to collect detailed medical and treatment history from a broad range of patients, including phenotypes or traits, treatment history and genetic information," said Dr. Juan Pascual, a neurologist and director of the Rare Brain Disorders Program at UT Southwestern's O'Donnell Brain Institute.

"Our data suggests that the single most important factor determining positive patient outcome is an early age of diagnosis, and also demonstrates that alternative dietary therapies can radically improve patient health over the long-term."

The results were published today in JAMA Neurology in an article titled: "Clinical Aspects of Glucose Transporter Type 1 Deficiency: Information from a Global Registry." UTA's Jianzhong Su, professor and chair of mathematics, and Dr. Jian Hao, a member of Dr. Su's research team, were co-authors on the paper.

The research results reflected data from a registry of 181 patients located worldwide, for the period from Dec. 1, 2013 to Dec. 1, 2016.

"We used several statistical methods tailored to address the age of onset of various forms of the disease, associated manifestations, natural history, treatment efficacy and diagnostic procedures," Dr. Su said.

"These factors were correlated in a predictive mathematical model designed to guide prognosis on the basis of clinical features at diagnosis," he added.

The three main novel results are:

  • The effectiveness of alternative dietary therapies, such as the "modified" Atkins diet. The term "modified" describes the lower carbohydrate limit compared to Atkins recommendations and the emphasis of high fat foods as is required on the ketogenic diet.
  • The existence of structural brain defects such as white matter abnormalities in one quarter of cases, as seen in MRI scans;
  • The favorable impact of early diagnosis and treatment regardless of treatment modality and mutation type.

These results challenge the current approaches to the disease, such as the perceived absolute requirement of a ketogenic or high-fat, low-carbohydrate diet, the assumed lack of structural brain defects and the potential existence of genotype: phenotype correlations.

"Patients who were diagnosed early and put on an adequate diet did very well," Dr. Su said. "Screening for this disease among babies with developmental delays or problems such as seizures within the first year of life could make a significant impact on outcomes."

The research was supported by a Service Package Grant from UT Southwestern's Center for Translational Medicine, which was given to the collaboration of Dr. Pascual's lab and Dr. Su's team to develop this analysis and additional research on individual patient's electroencephalogram or EEG imaging analysis to localize the sources of abnormal brain signals.

Morteza Khaledi, dean of UTA's College of Science, underlined the importance of this work in the context of UTA's strategic themes of health and the human condition and data-driven discovery within the Strategic Plan 2020: Bold Solutions|Global Impact.

"The work of Dr. Su's team in mathematical analysis gave the researchers the power to extract meaningful conclusions from large data sets with a very high level of rigor," Khaledi said. "These trends and associations may not have been seen in other ways."

###

About The University of Texas at Arlington

The University of Texas at Arlington is a Carnegie Research-1 "highest research activity" institution. With a projected global enrollment of close to 57,000, UTA is one of the largest institutions in the state of Texas. Guided by its Strategic Plan 2020 Bold Solutions|Global Impact, UTA fosters interdisciplinary research and education within four broad themes: health and the human condition, sustainable urban communities, global environmental impact, and data-driven discovery. UTA was recently cited by U.S. News & World Report as having the second lowest average student debt among U.S. universities. U.S. News & World Report lists UTA as having the fifth highest undergraduate diversity index among national universities. The University is a Hispanic-Serving Institution and is ranked as the top four-year college in Texas for veterans on Military Times' 2017 Best for Vets list.

Media Contact

Louisa Kellie
[email protected]
817-524-8926
@utarlington

http://www.uta.edu

Original Source

http://www.uta.edu/news/releases/2017/04/JAMA%20Neurology%20Su.php http://dx.doi.org/10.1001/jamaneurol.2017.0298

Share12Tweet7Share2ShareShareShare1

Related Posts

Oleanolic Acid: A Multi-Strategy Weapon Against Cancer

November 9, 2025
Embryonic Heat Manipulation: Metabolic Programming Insights

Embryonic Heat Manipulation: Metabolic Programming Insights

November 9, 2025

Weight Loss Medications Safe for Patients with High Triglycerides: No Increased Risk of Pancreatitis or Cardiac Events

November 9, 2025

Exploring Social Support’s Impact on Geriatric Cancer Patients

November 9, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    315 shares
    Share 126 Tweet 79
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    207 shares
    Share 83 Tweet 52
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    139 shares
    Share 56 Tweet 35
  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1303 shares
    Share 520 Tweet 325

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Oleanolic Acid: A Multi-Strategy Weapon Against Cancer

Embryonic Heat Manipulation: Metabolic Programming Insights

Weight Loss Medications Safe for Patients with High Triglycerides: No Increased Risk of Pancreatitis or Cardiac Events

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 69 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.